H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Innoviva today and set a price target of $45.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ram Selvaraju has given his Buy rating due to a combination of factors, primarily driven by Innoviva’s strong financial performance in the third quarter of 2025. The company’s revenue and earnings significantly surpassed expectations, with top-line revenue reaching $107.8 million compared to the estimated $93.6 million. Innoviva’s net earnings per diluted share also exceeded forecasts, coming in at $1.06 against a predicted $0.51. This robust performance has led to an upward revision of the full-year 2025 revenue forecast to approximately $400 million.
Furthermore, Innoviva’s financial health is underscored by its substantial cash reserves of $476.5 million, which supports its growth initiatives. The company’s proprietary products, particularly GIAPREZA and ZEVTERA, are expected to contribute to future growth, with ZEVTERA anticipated to resume strong sales growth. Additionally, the respiratory product royalty stream has outperformed projections, highlighting the durability of this revenue source. The upcoming regulatory decision on zoliflodacin, with a high probability of approval, also presents a potential value driver for Innoviva.
In another report released on November 6, Oppenheimer also maintained a Buy rating on the stock with a $35.00 price target.